Bivalirudin in peripheral vascular interventions: A single center experience

Journal of Invasive Cardiology

Volumn 15, Issue 7, 2003, Pages 401-404

  Shammas, Nicolas W ^a   Lemke, Jon H ^b   Dippel, Eric J ^b   McKinney, Dawn E ^b   Takes, Vickie S ^b   Youngblut, Monica ^b   Harris, Melodee ^b  

^a Cardiovascular Medicine Davenport   (United States)

^b NONE

Author keywords

Bivalirudin; Major bleeding; Peripheral angioplasty; Vascular complications

Indexed keywords

HEPARIN; HIRULOG;

ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY; ANTICOAGULATION; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; CLAUDICATION; CLINICAL ARTICLE; DEATH; EMBOLISM; FEMALE; HUMAN; LEG ULCER; LIMB AMPUTATION; LIMB SALVAGE; MALE; REVASCULARIZATION; SAFETY; SALVAGE THERAPY; STROKE; THROMBOSIS; THROMBUS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ANTITHROMBINS; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 0038163452     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Marmur JD. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. J Invas Cardiol 2002;14(Suppl B):8B-18B.
2. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invas Cardiol 2003;15:242-246.
3. Matsi PJ, Manninen HI. Complications of lower-limb percutaneous transluminal angioplasty: A prospective analysis of 410 procedures on 295 consecutive patients. Cardiovasc Intervent Radiol 1998;21:361-366.
4. Gutteridge W, Torrie EP, Galland RB. Cumulative risk of bypass, amputation or death following percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 1997;14:134-139.
5. Axisa B, Fishwick G, Bolia A, et al. Complications following peripheral angioplasty. Ann R Coll Surg Engl 2002;84:39-42.
6. Morse MH, Jeans WD, Cole SE, et al. Complications in percutaneous transluminal angioplasty: Relationships with patient age. Br J Radiol 1991;64:5-9.
7. Hasson JE, Acher CW, Wojtowycz M, et al. Lower extremity percutaneous transluminal angioplasty: Multifactorial analysis of morbidity and mortality. Surgery 1990;108:748-752.
8. Boyer L, Therre T, Garcier JM, et al. Infrapopliteal percutaneous transluminal angioplasty for limb salvage. Acta Radiol 2000;41:73-77.
9. Greenfield AJ. Femoral, popliteal, and tibial arteries: Percutaneous transluminal angioplasty. Am J Roentgenol 1980;135:927-935.
10. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959.
11. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa during percutaneous coronary intervention; The REPLACE-2 randomized trial. JAMA 2003;289:853-863.
12. Grubbs G. Single center experience with bivalirudin anticoagulation in peripheral vascular interventions: Possible benefits over unfractionated heparin. Poster presented at Cardiovascular Revascularization Therapy conference; January 26-29, 2003, Washington, D.C.
13. Knopf W. Joseph's Hospital experience: Direct thrombin inhibitors in ACS and PCI: The case for bivalirudin replacing unfracfionated heparin in PCI. Paper presented at Transcatheter Cardiovascular Therapeutics 14th Annual Scientific Symposium; September 24-28, 2002; Washington, D.C.
14. Allie D. Bivalirudin as sole anticoagulant in peripheral vascular disease: A safe and feasible alternative in renal and iliac interventions. Presented at American College of Cardiology 52nd Annual Scientific Session; March 30-April 2, 2003, Chicago, IL.
15. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.